Enanta Pharmaceuticals Files 10-Q for Period Ending December 31, 2023

TL;DR

<b>Enanta Pharmaceuticals filed its Q1 2024 10-Q, detailing financial instruments and equity, including royalty agreements.</b>

AI Summary

ENANTA PHARMACEUTICALS INC (ENTA) filed a Quarterly Report (10-Q) with the SEC on February 8, 2024. Enanta Pharmaceuticals filed its 10-Q report for the period ending December 31, 2023. The filing includes data related to various financial instruments and equity components. Specific fair value inputs for Level 1, Level 2, and Level 3 assets are detailed. The report references the Omers Royalty Sale Agreement and Omers Royalty Purchase Agreement. Information on unvested performance shares and restricted stock units is provided for different periods.

Why It Matters

For investors and stakeholders tracking ENANTA PHARMACEUTICALS INC, this filing contains several important signals. This filing provides a snapshot of Enanta's financial position and equity structure as of December 31, 2023, crucial for investors assessing the company's stability and valuation. The detailed breakdown of fair value inputs and specific agreements like the Omers Royalty Sale offers insights into the company's financial strategies and potential future revenue streams.

Risk Assessment

Risk Level: low — ENANTA PHARMACEUTICALS INC shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not indicate any immediate or significant financial distress or unexpected events.

Analyst Insight

Monitor future filings for updates on the performance of assets and the impact of royalty agreements on financial results.

Key Numbers

• 2023-12-31 — Reporting Period End Date (Conformed Period of Report)
• 2024-02-08 — Filing Date (Filed as of Date)
• Level 3 — Fair Value Input Level (Fair value inputs for money market funds)
• Level 1 — Fair Value Input Level (Fair value inputs for corporate debt securities)

Key Players & Entities

• ENANTA PHARMACEUTICALS INC (company) — Filer
• 20231231 (date) — Conformed Period of Report
• 20240208 (date) — Filed as of Date
• 500 ARSENAL STREET (address) — Business Address
• WATERTOWN (city) — Business Address City
• MA (state) — Business Address State
• 02472 (zip_code) — Business Address Zip
• Omers Royalty Sale Agreement (agreement) — Referenced Agreement

Forward-Looking Statements

• Enanta Pharmaceuticals Inc. will continue to report net losses in the near term due to ongoing high R&D expenditures. (Enanta Pharmaceuticals Inc.) — high confidence, target: 2024-09-30
• The company's cash and marketable securities will continue to decline if current spending rates persist without new revenue streams. (Enanta Pharmaceuticals Inc.) — medium confidence, target: 2024-06-30

FAQ

Industry Context

Enanta Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of small molecule anti-infective drug candidates.

Regulatory Implications

The filing is a standard 10-Q report under the Securities Exchange Act of 1934, requiring public companies to provide quarterly financial updates.

What Investors Should Do

1. Review the detailed fair value disclosures for financial assets and liabilities.
2. Analyze the impact of the Omers Royalty Sale and Purchase Agreements on the company's financial statements.
3. Track the vesting and grant of equity awards, such as RSUs and performance shares.

Year-Over-Year Comparison

This is the initial 10-Q filing for the fiscal quarter ending December 31, 2023, following the previous period's filings.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share ENTA NASDAQ Indicate by

Filing Documents

• enta-20231231.htm (10-Q) — 1244KB
• enta-ex31_1.htm (EX-31.1) — 11KB
• enta-ex31_2.htm (EX-31.2) — 11KB
• enta-ex32_1.htm (EX-32.1) — 10KB
• img216065237_0.jpg (GRAPHIC) — 79KB
• 0000950170-24-012796.txt (&nbsp;) — 6012KB
• enta-20231231.xsd (EX-101.SCH) — 920KB
• enta-20231231_htm.xml (XML) — 1018KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26 PART II. OTHER INFORMATION Item 1A.

Risk Factors

Risk Factors 26 Item 5. Other Information 27 Item 6. Exhibits 28

Signatures

Signatures 29 NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q ("Quarterly Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified by words such as "anticipate," "believe," "continue," "could," "design," "estimate," "expect," "intend," "may," "plan," "potentially," "predict," "project," "should," "will" or the negative of these terms or other similar expressions. We caution you that the foregoing list may not encompass all of the forward-looking statements made in this Quarterly Report. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2023 and as updated in Item 1A herein. 2 PAR T I—UNAUDITED FINANCIAL INFORMATION IT EM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ENANTA PHARMACEUTICALS, INC. CONDENSED CONS OLIDATED BALANCE SHEETS (unaudited) (in thousands, except per share data) December 31, September 30, 2023 2023 Assets Current assets: Cash and cash equivalents $ 39,933 $ 85,388 Short-term marketable securities 297,218 284,522 Accounts receivable 8,173 8,614 Prepa

View Full Filing

View this 10-Q filing on SEC EDGAR